ArticleThe Journal of antibiotics2026
Stepwise accumulation of SecA mutations enables high-stringency azide-based selection in Escherichia coli.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global spread of multidrug-resistant bacteria has reduced the effectiveness of many conventional antibiotics and complicated genetic analyses that rely on antibiotic resistance genes as selection markers. Genetic selection systems that do not rely on antibiotic-resistance genes are therefore increasingly important, particularly for multidrug-resistant strains. Sodium azide (Az) inhibits the essential ATPase SecA, but previously reported secA mutations confer only limited resistance and have not been developed into practical plasmid-based markers; plasmid-borne secA (F598L) confers only marginal resistance in an Az-sensitive background. Here, we show that this limited resistance results from coexistence of plasmid-derived mutant SecA with chromosomal wild-type SecA, which attenuates the resistant phenotype. The combination of F598L with a newly identified G516C mutation markedly enhanced Az resistance. Chromosomal replacement with secA (G516C/F598L) confirmed that wild-type SecA suppresses the resistant phenotype when coexpressed. Using error-prone PCR, we further generated cumulative SecA mutants and identified a variant harboring five amino acid substitutions (G516C, F598L, L279P, S678I, and A867G) that supported substantially improved, though progressively reduced, growth in liquid culture at Az concentrations up to 200 µg ml
Identifiers
42902037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.